ID   TY3H_RAT                Reviewed;         498 AA.
AC   P04177;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-OCT-2024, entry version 195.
DE   RecName: Full=Tyrosine 3-monooxygenase;
DE            EC=1.14.16.2 {ECO:0000269|PubMed:10933781, ECO:0000269|PubMed:11922614};
DE   AltName: Full=Tyrosine 3-hydroxylase;
DE            Short=TH;
GN   Name=Th;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2857492; DOI=10.1073/pnas.82.2.617;
RA   Grima B., Lamouroux A., Blanot F., Faucon Biguet N., Mallet J.;
RT   "Complete coding sequence of rat tyrosine hydroxylase mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:617-621(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Anton X.X., Manaster J.S., Kordower X.X., Markham X.X., Bredesen D.E.;
RL   Submitted (JUL-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PROTEIN SEQUENCE OF 2-12; 284-298 AND 452-459, CLEAVAGE OF INITIATOR
RP   METHIONINE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Pheochromocytoma;
RA   Bienvenut W.V., von Kriegsheim A.F., Kolch W.;
RL   Submitted (AUG-2006) to UniProtKB.
RN   [4]
RP   PHOSPHORYLATION AT SER-19; SER-31 AND SER-40.
RX   PubMed=1672315; DOI=10.1016/s0021-9258(19)67644-1;
RA   Haycock J.W., Haycock D.A.;
RT   "Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-
RT   site phosphorylation in vivo and in synaptosomes.";
RL   J. Biol. Chem. 266:5650-5657(1991).
RN   [5]
RP   PHOSPHORYLATION AT SER-19 AND SER-40, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=11502746; DOI=10.1074/jbc.m105280200;
RA   Bevilaqua L.R., Graham M.E., Dunkley P.R., von Nagy-Felsobuki E.I.,
RA   Dickson P.W.;
RT   "Phosphorylation of Ser(19) alters the conformation of tyrosine hydroxylase
RT   to increase the rate of phosphorylation of Ser(40).";
RL   J. Biol. Chem. 276:40411-40416(2001).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 156-498 IN COMPLEX WITH IRON, AND
RP   SUBUNIT.
RX   PubMed=9228951; DOI=10.1038/nsb0797-578;
RA   Goodwill K.E., Sabatier C., Marks C., Raag R., Fitzpatrick P.F.,
RA   Stevens R.C.;
RT   "Crystal structure of tyrosine hydroxylase at 2.3 A and its implications
RT   for inherited neurodegenerative diseases.";
RL   Nat. Struct. Biol. 4:578-585(1997).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF
RP   GLN-310; HIS-323 AND ASP-425, AND SUBSTRATE SPECIFICITY.
RX   PubMed=10933781; DOI=10.1021/bi000493k;
RA   Daubner S.C., Melendez J., Fitzpatrick P.F.;
RT   "Reversing the substrate specificities of phenylalanine and tyrosine
RT   hydroxylase: aspartate 425 of tyrosine hydroxylase is essential for L-DOPA
RT   formation.";
RL   Biochemistry 39:9652-9661(2000).
RN   [8]
RP   CATALYTIC ACTIVITY, FUNCTION, MUTAGENESIS OF TRP-372, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11922614; DOI=10.1006/bbrc.2002.6719;
RA   Daubner S.C., Moran G.R., Fitzpatrick P.F.;
RT   "Role of tryptophan hydroxylase phe313 in determining substrate
RT   specificity.";
RL   Biochem. Biophys. Res. Commun. 292:639-641(2002).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15496595; DOI=10.1093/jb/mvh113;
RA   Tsudzuki T., Tsujita M.;
RT   "Isoosmotic isolation of rat brain synaptic vesicles, some of which contain
RT   tyrosine hydroxylase.";
RL   J. Biochem. 136:239-243(2004).
RN   [10]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-19; SER-31 AND SER-40.
RX   PubMed=21392500; DOI=10.1016/j.bbrc.2011.03.020;
RA   Nakashima A., Mori K., Kaneko Y.S., Hayashi N., Nagatsu T., Ota A.;
RT   "Phosphorylation of the N-terminal portion of tyrosine hydroxylase triggers
RT   proteasomal digestion of the enzyme.";
RL   Biochem. Biophys. Res. Commun. 407:343-347(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 156-498 IN COMPLEX WITH IRON.
RX   PubMed=9753429; DOI=10.1021/bi981462g;
RA   Goodwill K.E., Sabatier C., Stevens R.C.;
RT   "Crystal structure of tyrosine hydroxylase with bound cofactor analogue and
RT   iron at 2.3 A resolution: self-hydroxylation of Phe300 and the pterin-
RT   binding site.";
RL   Biochemistry 37:13437-13445(1998).
RN   [12] {ECO:0007744|PDB:2MDA}
RP   STRUCTURE BY NMR OF 65-159.
RX   PubMed=24361276; DOI=10.1016/j.jmb.2013.12.015;
RA   Zhang S., Huang T., Ilangovan U., Hinck A.P., Fitzpatrick P.F.;
RT   "The solution structure of the regulatory domain of tyrosine hydroxylase.";
RL   J. Mol. Biol. 426:1483-1497(2014).
CC   -!- FUNCTION: Catalyzes the conversion of L-tyrosine to L-
CC       dihydroxyphenylalanine (L-Dopa), the rate-limiting step in the
CC       biosynthesis of cathecolamines, dopamine, noradrenaline, and
CC       adrenaline. Uses tetrahydrobiopterin and molecular oxygen to convert
CC       tyrosine to L-Dopa (By similarity). In addition to tyrosine, is able to
CC       catalyze the hydroxylation of phenylalanine and tryptophan but with
CC       lower specificity (PubMed:10933781, PubMed:11922614). Positively
CC       regulates the regression of retinal hyaloid vessels during postnatal
CC       development (By similarity). {ECO:0000250|UniProtKB:P07101,
CC       ECO:0000250|UniProtKB:P24529, ECO:0000269|PubMed:10933781,
CC       ECO:0000269|PubMed:11922614}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin + L-tyrosine + O2 =
CC         (4aS,6R)-4a-hydroxy-L-erythro-5,6,7,8-tetrahydrobiopterin + L-dopa;
CC         Xref=Rhea:RHEA:18201, ChEBI:CHEBI:15379, ChEBI:CHEBI:15642,
CC         ChEBI:CHEBI:57504, ChEBI:CHEBI:58315, ChEBI:CHEBI:59560;
CC         EC=1.14.16.2; Evidence={ECO:0000269|PubMed:10933781,
CC         ECO:0000269|PubMed:11922614};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18202;
CC         Evidence={ECO:0000305|PubMed:11922614};
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:9228951};
CC   -!- ACTIVITY REGULATION: Inhibited in feedback fashion by the catecholamine
CC       neurotransmitters, especially by dopamine in competition with
CC       tetrahydrobiopterin. Phosphorylation of several Ser/Thr residues in the
CC       N-terminus regulates the catalytic activity. Ser-31 and Ser-40 are
CC       readily phosphorylated to activate the catalytic activity. A cysteine
CC       modification induced by N-ethylmaleimide (NEM), inhibits tyrosine 3-
CC       monooxygenase activity through the modification of the Cys-177.
CC       {ECO:0000250|UniProtKB:P07101}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=96 uM for phenylalanine {ECO:0000269|PubMed:10933781};
CC         KM=210 uM for tryptophan {ECO:0000269|PubMed:11922614};
CC         KM=16 uM for tyrosine {ECO:0000269|PubMed:10933781};
CC   -!- PATHWAY: Catecholamine biosynthesis; dopamine biosynthesis; dopamine
CC       from L-tyrosine: step 1/2. {ECO:0000250|UniProtKB:P07101}.
CC   -!- SUBUNIT: Homotetramer (PubMed:9228951). Interacts (when phosphorylated
CC       at Ser-19) with YWHAG; one YWHAG dimer bounds to one TH tetramer this
CC       interaction may influence the phosphorylation and dephosphorylation of
CC       other sites (By similarity). {ECO:0000250|UniProtKB:P07101,
CC       ECO:0000269|PubMed:9228951}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:P24529}. Nucleus {ECO:0000269|PubMed:21392500}.
CC       Cell projection, axon {ECO:0000250|UniProtKB:P24529}. Cytoplasm
CC       {ECO:0000269|PubMed:15496595, ECO:0000269|PubMed:21392500}. Cytoplasmic
CC       vesicle, secretory vesicle, synaptic vesicle
CC       {ECO:0000269|PubMed:15496595}. Note=When phosphorylated at Ser-19 shows
CC       a nuclear distribution and when phosphorylated at Ser-31 as well as at
CC       Ser-40 shows a cytosolic distribution (PubMed:21392500). Expressed in
CC       dopaminergic axons and axon terminals (By similarity).
CC       {ECO:0000250|UniProtKB:P07101, ECO:0000269|PubMed:21392500}.
CC   -!- PTM: Phosphorylated on Ser-19, Ser-31 and Ser-40 by several protein
CC       kinases with different site specificities. Phosphorylation at Ser-31
CC       and Ser-40 leads to an increase of TH activity. Phosphorylation at Ser-
CC       40 activates the enzyme and also counteracts the feedback inhibition of
CC       TH by catecholamines (By similarity). Phosphorylation of Ser-19 and
CC       Ser-31 triggers the proteasomal degradation of TH through the
CC       ubiquitin-proteasome pathway (PubMed:21392500). Phosphorylation at Ser-
CC       31 facilitates transport of TH from the soma to the nerve terminals via
CC       the microtubule network (By similarity). Phosphorylation at Ser-19
CC       induces the high-affinity binding to the 14-3-3 protein YWHAG; this
CC       interaction may influence the phosphorylation and dephosphorylation of
CC       other sites (By similarity). Ser-19 increases the phosphorylation at
CC       Ser-40 in a hierarchical manner, leading to increased activity
CC       (PubMed:11502746, PubMed:1672315). {ECO:0000250|UniProtKB:P07101,
CC       ECO:0000269|PubMed:11502746, ECO:0000269|PubMed:1672315,
CC       ECO:0000269|PubMed:21392500}.
CC   -!- SIMILARITY: Belongs to the biopterin-dependent aromatic amino acid
CC       hydroxylase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M10244; AAA42257.1; -; mRNA.
DR   EMBL; L22651; AAA42258.1; -; mRNA.
DR   PIR; A00510; WHRTY.
DR   RefSeq; NP_036872.1; NM_012740.3.
DR   PDB; 1TOH; X-ray; 2.30 A; A=156-498.
DR   PDB; 2MDA; NMR; -; A/B=65-159.
DR   PDB; 2TOH; X-ray; 2.30 A; A=156-498.
DR   PDBsum; 1TOH; -.
DR   PDBsum; 2MDA; -.
DR   PDBsum; 2TOH; -.
DR   AlphaFoldDB; P04177; -.
DR   BMRB; P04177; -.
DR   SMR; P04177; -.
DR   BioGRID; 247158; 2.
DR   CORUM; P04177; -.
DR   IntAct; P04177; 3.
DR   MINT; P04177; -.
DR   STRING; 10116.ENSRNOP00000027682; -.
DR   BindingDB; P04177; -.
DR   ChEMBL; CHEMBL2462; -.
DR   GlyGen; P04177; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P04177; -.
DR   PhosphoSitePlus; P04177; -.
DR   jPOST; P04177; -.
DR   PaxDb; 10116-ENSRNOP00000027682; -.
DR   Ensembl; ENSRNOT00000027682.6; ENSRNOP00000027682.3; ENSRNOG00000020410.6.
DR   Ensembl; ENSRNOT00055053621; ENSRNOP00055044346; ENSRNOG00055030903.
DR   Ensembl; ENSRNOT00060054459; ENSRNOP00060045080; ENSRNOG00060031396.
DR   Ensembl; ENSRNOT00065055278; ENSRNOP00065045469; ENSRNOG00065032083.
DR   GeneID; 25085; -.
DR   KEGG; rno:25085; -.
DR   UCSC; RGD:3853; rat.
DR   AGR; RGD:3853; -.
DR   CTD; 7054; -.
DR   RGD; 3853; Th.
DR   eggNOG; KOG3820; Eukaryota.
DR   GeneTree; ENSGT00950000182885; -.
DR   HOGENOM; CLU_023198_0_1_1; -.
DR   InParanoid; P04177; -.
DR   OMA; VRYNPHT; -.
DR   OrthoDB; 275463at2759; -.
DR   PhylomeDB; P04177; -.
DR   TreeFam; TF313327; -.
DR   BRENDA; 1.14.16.2; 5301.
DR   Reactome; R-RNO-209905; Catecholamine biosynthesis.
DR   SABIO-RK; P04177; -.
DR   UniPathway; UPA00747; UER00733.
DR   EvolutionaryTrace; P04177; -.
DR   PRO; PR:P04177; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000020410; Expressed in brain and 3 other cell types or tissues.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISO:RGD.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISO:RGD.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0033162; C:melanosome membrane; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:RGD.
DR   GO; GO:0043195; C:terminal bouton; IDA:RGD.
DR   GO; GO:0016597; F:amino acid binding; IDA:RGD.
DR   GO; GO:0035240; F:dopamine binding; IPI:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0008199; F:ferric iron binding; IDA:RGD.
DR   GO; GO:0008198; F:ferrous iron binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; TAS:RGD.
DR   GO; GO:0004497; F:monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0019825; F:oxygen binding; IDA:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0036094; F:small molecule binding; IDA:DisProt.
DR   GO; GO:0034617; F:tetrahydrobiopterin binding; IDA:RGD.
DR   GO; GO:0004511; F:tyrosine 3-monooxygenase activity; IDA:RGD.
DR   GO; GO:0015842; P:aminergic neurotransmitter loading into synaptic vesicle; IDA:RGD.
DR   GO; GO:0009887; P:animal organ morphogenesis; ISO:RGD.
DR   GO; GO:0042423; P:catecholamine biosynthetic process; IDA:RGD.
DR   GO; GO:0071312; P:cellular response to alkaloid; IEP:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEP:RGD.
DR   GO; GO:0071316; P:cellular response to nicotine; IEP:RGD.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0042745; P:circadian sleep/wake cycle; IEP:RGD.
DR   GO; GO:0050890; P:cognition; IEP:RGD.
DR   GO; GO:0042416; P:dopamine biosynthetic process; ISO:RGD.
DR   GO; GO:0006585; P:dopamine biosynthetic process from tyrosine; IDA:RGD.
DR   GO; GO:0042755; P:eating behavior; ISO:RGD.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; ISO:RGD.
DR   GO; GO:0042418; P:epinephrine biosynthetic process; ISO:RGD.
DR   GO; GO:0042462; P:eye photoreceptor cell development; ISO:RGD.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEP:RGD.
DR   GO; GO:0016137; P:glycoside metabolic process; IEP:RGD.
DR   GO; GO:0007507; P:heart development; IDA:RGD.
DR   GO; GO:1990384; P:hyaloid vascular plexus regression; ISS:UniProtKB.
DR   GO; GO:0033076; P:isoquinoline alkaloid metabolic process; IEP:RGD.
DR   GO; GO:0007612; P:learning; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0007617; P:mating behavior; ISO:RGD.
DR   GO; GO:0007613; P:memory; ISO:RGD.
DR   GO; GO:0042421; P:norepinephrine biosynthetic process; ISO:RGD.
DR   GO; GO:0018963; P:phthalate metabolic process; IEP:RGD.
DR   GO; GO:0052314; P:phytoalexin metabolic process; IEP:RGD.
DR   GO; GO:0008016; P:regulation of heart contraction; ISO:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0001975; P:response to amphetamine; IEP:RGD.
DR   GO; GO:0051412; P:response to corticosterone; IEP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0045472; P:response to ether; IEP:RGD.
DR   GO; GO:0070848; P:response to growth factor; IEP:RGD.
DR   GO; GO:0009635; P:response to herbicide; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IDA:RGD.
DR   GO; GO:0035902; P:response to immobilization stress; IEP:RGD.
DR   GO; GO:0017085; P:response to insecticide; IEP:RGD.
DR   GO; GO:0035900; P:response to isolation stress; IEP:RGD.
DR   GO; GO:0009416; P:response to light stimulus; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0010038; P:response to metal ion; IEP:RGD.
DR   GO; GO:0035094; P:response to nicotine; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0046684; P:response to pyrethroid; IEP:RGD.
DR   GO; GO:0009651; P:response to salt stress; IEP:RGD.
DR   GO; GO:0048545; P:response to steroid hormone; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0010043; P:response to zinc ion; IEP:RGD.
DR   GO; GO:0035176; P:social behavior; IEP:RGD.
DR   GO; GO:0006665; P:sphingolipid metabolic process; IEP:RGD.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; ISO:RGD.
DR   GO; GO:0042214; P:terpene metabolic process; IEP:RGD.
DR   GO; GO:0007601; P:visual perception; ISO:RGD.
DR   CDD; cd04930; ACT_TH; 1.
DR   CDD; cd03345; eu_TyrOH; 1.
DR   DisProt; DP00094; -.
DR   Gene3D; 3.30.70.260; -; 1.
DR   Gene3D; 1.10.800.10; Aromatic amino acid hydroxylase; 1.
DR   InterPro; IPR045865; ACT-like_dom_sf.
DR   InterPro; IPR001273; ArAA_hydroxylase.
DR   InterPro; IPR018301; ArAA_hydroxylase_Fe/CU_BS.
DR   InterPro; IPR036951; ArAA_hydroxylase_sf.
DR   InterPro; IPR036329; Aro-AA_hydroxylase_C_sf.
DR   InterPro; IPR019774; Aromatic-AA_hydroxylase_C.
DR   InterPro; IPR041903; Eu_TyrOH_cat.
DR   InterPro; IPR049321; TH_ACT.
DR   InterPro; IPR005962; Tyr_3_mOase.
DR   InterPro; IPR019773; Tyrosine_3-monooxygenase-like.
DR   InterPro; IPR021164; Tyrosine_hydroxylase_CS.
DR   NCBIfam; TIGR01269; Tyr_3_monoox; 1.
DR   PANTHER; PTHR11473; AROMATIC AMINO ACID HYDROXYLASE; 1.
DR   PANTHER; PTHR11473:SF18; TYROSINE 3-MONOOXYGENASE; 1.
DR   Pfam; PF00351; Biopterin_H; 1.
DR   Pfam; PF21417; TH_ACT; 1.
DR   Pfam; PF12549; TOH_N; 2.
DR   PIRSF; PIRSF000336; TH; 1.
DR   PRINTS; PR00372; FYWHYDRXLASE.
DR   SUPFAM; SSF55021; ACT-like; 1.
DR   SUPFAM; SSF56534; Aromatic aminoacid monoxygenases, catalytic and oligomerization domains; 1.
DR   PROSITE; PS00367; BH4_AAA_HYDROXYL_1; 1.
DR   PROSITE; PS51410; BH4_AAA_HYDROXYL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Catecholamine biosynthesis; Cell projection; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Iron; Metal-binding;
KW   Monooxygenase; Neurotransmitter biosynthesis; Nucleus; Oxidoreductase;
KW   Phosphoprotein; Reference proteome; Synapse.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.3"
FT   CHAIN           2..498
FT                   /note="Tyrosine 3-monooxygenase"
FT                   /id="PRO_0000205564"
FT   REGION          1..31
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         331
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000269|PubMed:9228951,
FT                   ECO:0000269|PubMed:9753429, ECO:0007744|PDB:1TOH,
FT                   ECO:0007744|PDB:2TOH"
FT   BINDING         336
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000269|PubMed:9228951,
FT                   ECO:0000269|PubMed:9753429, ECO:0007744|PDB:1TOH,
FT                   ECO:0007744|PDB:2TOH"
FT   BINDING         376
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000269|PubMed:9228951,
FT                   ECO:0000269|PubMed:9753429, ECO:0007744|PDB:1TOH,
FT                   ECO:0007744|PDB:2TOH"
FT   SITE            425
FT                   /note="Important for substrate specificity"
FT                   /evidence="ECO:0000269|PubMed:10933781"
FT   MOD_RES         19
FT                   /note="Phosphoserine; by CaMK2"
FT                   /evidence="ECO:0000269|PubMed:11502746,
FT                   ECO:0000269|PubMed:1672315, ECO:0000269|PubMed:21392500"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:1672315,
FT                   ECO:0000269|PubMed:21392500"
FT   MOD_RES         40
FT                   /note="Phosphoserine; by CaMK2 and PKA"
FT                   /evidence="ECO:0000269|PubMed:11502746,
FT                   ECO:0000269|PubMed:1672315, ECO:0000269|PubMed:21392500"
FT   MOD_RES         472
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P24529"
FT   MUTAGEN         310
FT                   /note="Q->H: Does not affect Vmax for phenylalanine.
FT                   Increases KM for phenylalanine."
FT                   /evidence="ECO:0000269|PubMed:10933781"
FT   MUTAGEN         323
FT                   /note="H->Y: Does not affect Vmax for phenylalaninet.
FT                   Increases KM for phenylalanine."
FT                   /evidence="ECO:0000269|PubMed:10933781"
FT   MUTAGEN         372
FT                   /note="W->F: Does not affect substrate specificity."
FT                   /evidence="ECO:0000269|PubMed:11922614"
FT   MUTAGEN         425
FT                   /note="D->V: Shifts substrate specificity from tyrosine to
FT                   phenylalanine."
FT                   /evidence="ECO:0000269|PubMed:10933781"
FT   STRAND          75..77
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   STRAND          80..85
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   STRAND          91..93
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   HELIX           98..106
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   STRAND          110..116
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   STRAND          119..122
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   STRAND          133..138
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   HELIX           141..150
FT                   /evidence="ECO:0007829|PDB:2MDA"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:2TOH"
FT   HELIX           171..176
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          177..179
FT                   /evidence="ECO:0007829|PDB:2TOH"
FT   TURN            193..196
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           198..213
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           227..247
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           250..262
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           273..283
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          287..290
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           297..304
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   TURN            305..307
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          308..311
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           329..335
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           337..340
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           343..356
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           361..372
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   TURN            373..377
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          379..382
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          385..388
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           391..394
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           397..403
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          405..412
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           415..419
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          425..427
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          430..436
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           438..450
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          457..461
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   TURN            462..465
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   STRAND          466..470
FT                   /evidence="ECO:0007829|PDB:1TOH"
FT   HELIX           473..496
FT                   /evidence="ECO:0007829|PDB:1TOH"
SQ   SEQUENCE   498 AA;  55966 MW;  17F7E003D29218C5 CRC64;
     MPTPSAPSPQ PKGFRRAVSE QDAKQAEAVT SPRFIGRRQS LIEDARKERE AAAAAAAAAV
     ASSEPGNPLE AVVFEERDGN AVLNLLFSLR GTKPSSLSRA VKVFETFEAK IHHLETRPAQ
     RPLAGSPHLE YFVRFEVPSG DLAALLSSVR RVSDDVRSAR EDKVPWFPRK VSELDKCHHL
     VTKFDPDLDL DHPGFSDQVY RQRRKLIAEI AFQYKHGEPI PHVEYTAEEI ATWKEVYVTL
     KGLYATHACR EHLEGFQLLE RYCGYREDSI PQLEDVSRFL KERTGFQLRP VAGLLSARDF
     LASLAFRVFQ CTQYIRHASS PMHSPEPDCC HELLGHVPML ADRTFAQFSQ DIGLASLGAS
     DEEIEKLSTV YWFTVEFGLC KQNGELKAYG AGLLSSYGEL LHSLSEEPEV RAFDPDTAAV
     QPYQDQTYQP VYFVSESFND AKDKLRNYAS RIQRPFSVKF DPYTLAIDVL DSPHTIQRSL
     EGVQDELHTL AHALSAIS
//
